President Biden continues to harbor the COVID-19 virus (SARS-CoV-2) in his body. He first contracted COVID-19 on July 21, two and a half weeks before the present. Is this because of immunosuppression – due to his heavily boosted status, or for some other reason? That being said, the single antiviral drug regime of Paxlovid may also be causing the virus to stay in his body for a long time, an effect otherwise referred to as “the rebound” effect:
“The hypothesis is that the immune system didn’t have a chance to see the full extent of the virus, since Paxlovid suppressed replication early in disease,” Dr. Roberts says. Scientists are studying the effects of longer treatment durations, longer periods of isolation, and other ways of managing the problem, he adds. (Scott Roberts, MD, a Yale Medicine infectious diseases specialist.)
I believe that the word “rebound” is a misnomer in this context. The virus has never left President Biden’s body. It is still circulating, it was just at a fairly undetectable level for a while. What could possibly go wrong? Oh, I know! Viruses resistant to Paxlovid are spawned, the virus population explodes and then the “rebound” effect is observed -only this time with Paxlovid resistant strains.
Paxlovid manufacturer Pfizer and the Food and Drug Administration have both acknowledged reports of rebound COVID-19 cases associated with the drug.
This is truly the worst case scenario for a single mechanism of action drug used as a therapy against COVID-19, as described in more detail below.
But it isn’t just that Paxlovid causes the virus to stick around for weeks on end, it doesn’t work very well either: “Warning! Biden’s Pushing Paxlovid, the Pfizer Flop Drug”
Upon launch, Pfizer said their new anti-viral drug Paxlovid cut hospitalization and death by 90%. An updated, more recent analysis from 1,153 patients (out of a possible 2,246 patients) showed a lackluster, non-significant 51% relative risk reduction.
A sub-group analysis of 721 vaccinated adults with at least one risk factor for progression to severe COVID-19 showed a non-significant relative risk reduction in hospitalization or death (treatment arm: 3/361; placebo: 7/360).
How can we control SARS-CoV-2’s evolution of resistance to drugs?
SARS-CoV-2 (the cause of COVID-19) is an RNA virus, just like HIV is an RNA virus. RNA viruses evolve very rapidly and have a lot of genetic mutations. And just like HIV, the COVID-19 virus evolves so quickly that it evolves right out from under single “mechanism of action” (single agent) drug therapy. When a patient begins taking Paxlovid, it appears that the drug keeps many of the viruses from reproducing. Because some of the new mutations happen to have a certain level of resistance to the drug, some viruses do survive. Because of COVID-19’s speedy evolution, the virus responds to selection pressures quickly. So, viruses that happen to survive the drug are favored and then resistant virus strains evolve within the patient. When a patient is immunosuppressed and doesn’t clear the virus (as seems to be happening with Paxlovid), then this evolution has a longer runway to evolve before the virus is cleared by the body. These new strains are then spread through out the population. So, other people can contract the escape mutant resistant lineage. A new variant is born.
When HIV single dose therapies failed, physicians soon realized that basic evolutionary theory leads to a solution from this dilemma. That is evolution of resistant viral strains can be delayed by prescribing a multi-drug therapy. That is why so many early, multi-drug treatment COVID-19 docs use drug cocktails.
So why is it, that the FDA (read below), knowing this – did not chose to exclude immunocompromised individuals from using the drug?
Severely immunocompromised patients can experience prolonged periods of SARS-CoV-2 replication, which may lead to rapid viral evolution. There are theoretical concerns that using a single antiviral agent in these patients may produce antiviral-resistant viruses. Additional studies are needed to assess this risk. The role of combination antiviral therapy or a longer treatment duration in treating severely immunocompromised patients is not yet known.
Right now, patients consuming the Pfizer drug as a single agent therapeutic are increasing the risk of spawning resistant escape mutant variants. If you want a case example of how this works – just look to President Biden and his current treatment plan. That is, round three of the current treatment plan. That is two and a half weeks of having circulating virus in his body. That virus is busy evolving to escape the drug and/or his vaccine.
Now, what we learned also from HIV is that the virus mutates so rapidly, that it evolves so quickly, that it evolves right out from under vaccines – particularly in immunosuppressed patients, who do not rapidly clear the virus. Then vaccine escape mutants are generated with are resistant to the vaccine. So, the fact that Paxlovid is prolonging the virus in the body can only lead to more vaccine escape mutants.
One might think that Pfizer and Moderna wanted to prolong this outbreak…
Naw, that would be too cynical, even for them, right?
“I think some clinicians have unfortunately written off Paxlovid as not a good option for patients who would very much benefit from it based on what is a misperception that it doesn’t work or doesn’t do a good job,” said Jennifer Nuzzo, an epidemiologist and director of the Pandemic Center at Brown University School of Public Health. “I just worry that we are robbing people of an important tool.”
I just worry that public health officials won’t bother to actually read the scientific literature, understand what an effective drug does and learn some basic principles about virology.
When will they ever learn?
Robert W Malone, MD, MS is the creator of mRNA and DNA vaccinations, as well as RNA as a medicine. He is a scientist, physician, author, podcaster, pundit, and activist and a believer in our fundamental right to free expression. This post was first published on Substack.
Read the document below:
Paxlovid-Is-Causing-Covid-Mutations
2 Responses
HIV-1 protease inhibitors (-navir) have their best efficacy against retroviruses.
NS3/4A protease inhibitors (-previr) have their best efficacy against hepatitis C.
Papain-like protease (PLpro) inhibitors have had efficacy in vitro but never in vivo.
3C-like protease (3CLpro) inhibitors (-trelvir) are also known as nonstructural protein 5 (NSP5) inhibitors or main protease (Mpro) inhibitors:
https://en.wikipedia.org/wiki/Protease_inhibitor_(pharmacology)
Pfizer’s PF-07321332 (nirmatrelvir) is a 3CL protease inhibitor that breaks down too rapidly in the human bloodstream without the addition of ritonavir:
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-covid-treatment-paxlovid-fails-prevent-infection-household-members-2022-04-29/
Pfizer’s PF-07304814 (intravenous nirmatrelvir) is a 3CL protease inhibitor that was halted prematurely in the ACTIV-3 trial because of both bad side effects and lack of efficacy:
https://www.fiercebiotech.com/biotech/pfizer-a-rare-covid-19-setback-dumps-paxlovid-s-intravenous-sibling-to-leave-activ-3-future
Enanta’s EDP-235 is a 3CL protease inhibitor that does not require the addition of ritonavir:
https://www.marketwatch.com/story/enanta-filed-patent-infringement-suit-against-pfizer-over-paxlovid-271655846242
https://finance.yahoo.com/chart/ENTA
Todos Medical’s Tollovir is, like vitamin B12, a “natural” 3CL protease inhibitor:
https://finance.yahoo.com/chart/TOMDF
Ascletis’ ASC-11 (requires ritonavir), Everest Medicines’ EDDC-2214 (no ritonavir), Pardes Bio’s PBI-0451 (no ritonavir), Sorrento’s STI-1558 (no ritonavir), and Sohei Heptares’ SH-879 (no ritonavir) have now all been tested in lab animals:
https://pbs.twimg.com/media/FSO8gmVVsAEMr__.jpg:large
China’s Y180, which has about the same EC50 (in vitro efficacy) as Pfizer’s nirmatrelvir, is a 3CL protease inhibitor that does not require the addition of ritonavir:
https://www.nature.com/articles/s41564-022-01119-7
Zhongsheng Pharma’s RAY1216, which has about the same EC50 (in vitro efficacy) as Pfizer’s nirmatrelvir, is a 3CL protease inhibitor that does not require the addition of ritonavir:
https://www.yicaiglobal.com/news/zhongsheng-pharma-gains-after-its-oral-covid-19-drug-gets-go-ahead-for-clinical-trials
Simcere Pharma’s SIM0417, which has about the same EC50 (in vitro efficacy) as Pfizer’s nirmatrelvir, is a 3CL protease inhibitor that does not require the addition of ritonavir:
https://finance.yahoo.com/news/simcere-pharma-hk-2096-novel-034000468.html
Shionogi’s S-217622, which has now been named, Xocova (ensitrelvir), is a 3CL protease inhibitor that does not require the addition of ritonavir and has an excellent EC50 (in vitro efficacy) of 0.29μM to 0.50μM, which is far superior to Pfizer’s nirmatrelvir, which has an EC50 (in vitro efficacy) of 6.76μM to 14.81μM:
https://en.wikipedia.org/wiki/3C-like_protease#As_a_treatment_target
https://en.wikipedia.org/wiki/ensitrelvir
https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00117
https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c00117/asset/images/acs.jmedchem.2c00117.social.jpeg_v03
https://www.valdostadailytimes.com/news/business/new-data-for-shionogi-s-covid-19-once-daily-oral-antiviral-s-217622-show-rapid/article_2ffd9953-866d-56f8-b786-8be36f583d9f.html
https://www.india.com/news/world/covid-pill-shows-rapid-clearance-of-infection-japanese-pharma-firm-shionogi-5356016/
https://www.medrxiv.org/content/10.1101/2022.05.17.22275027v1.full
https://c19early.com/mukae.html
https://c19early.com/en
In the past, all HIV-1 protease inhibitors had their best efficacy against retroviruses and failed against RNA viruses. Kaletra (lopinavir plus ritonavir) is a combination of two HIV-1 protease inhibitors that had some efficacy against retroviruses but failed against RNA viruses:
https://www.sciencedirect.com/science/article/pii/S2095809920300631
https://www.tribuneindia.com/news/health/hiv-drugs-lopinavir-ritonavir-show-no-promise-for-covid-treatment-reveals-uks-recovery-trial-106659
https://www.medrxiv.org/content/10.1101/2020.07.23.20153932v1.full
https://pubmed.ncbi.nlm.nih.gov/33264556/
Pfizer’s 3CL protease inhibitor, PF-07321332 (nirmatrelvir), needs to be swallowed together with the HIV-1 protease inhibitor, ritonavir:
https://www.drugs.com/sfx/ritonavir-side-effects.html
https://www.drugs.com/comments/ritonavir/
Pfizer’s Paxlovid (nirmatrelvir plus ritonavir) comprises of 3 pills that need to be swallowed twice daily for never more than 5 days.
Shionogi’s Xocova (ensitrelvir) comprises of just 1 pill that needs to be swallowed once each day for 5 days.
In Emi Takashita’s in vitro study, Merck’s molnupiravir was 17.84 times more effective than Pfizer’s nirmatrelvir against the Delta variant and 29.56 times more effective than Pfizer’s nirmatrelvir against the Omicron variant. All 10 monoclonal antibody drugs in Emi Takashita’s Japanese in vitro study failed even more severely against the Omicron variant than Pfizer’s nirmatrelvir:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809508/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809508/table/t1/
https://igorchudov.substack.com/p/paxlovid-snake-oil-of-the-21st-century?
In the past, all HIV-1 protease inhibitors, including RITONAVIR, were cell-damaging pro-oxidants and had a long list of BAD SIDE EFFECTS (artery wall damage, arthralgia, bleeding among hemophiliacs, blood clots among normal people, bone damage, brain damage, dysgeusia, endocrine system damage, endoplasmic reticulum damage, fatty liver, gingivitis, Golgi damage, hair loss, hearing loss, heart damage, hyperlipidemia, hypertension, hypertriglyceridemia, insulin resistance, kidney damage, kidney stones, liver damage, metallic mouth, mitochondria damage, muscle damage, nervous system damage, oxidative stress, pancreatitis, sexual dysfunction, skin damage, vision loss):
https://h-i-v.net/treatment/protease-inhibitors
https://www.theatlantic.com/health/archive/2022/05/pfizer-paxlovid-covid-pill-side-effects/629772/
RITONAVIR causes platelet aggregation (blood clots):
https://www.aidsmap.com/news/apr-2002/protease-inhibitor-patients-higher-risk-thrombosis
https://www.sciencedirect.com/science/article/abs/pii/S0049384818304110
RITONAVIR causes bleeding in hemophiliacs, who can catch HIV or hepatitis from their frequent blood transfusions:
https://journals.lww.com/pidj/Fulltext/1998/10000/SPONTANEOUS_BLEEDING_ASSOCIATED_WITH_THE_USE_OF.21.aspx
RITONAVIR causes endothelial dysfunction (artery wall damage):
https://pharmrev.aspetjournals.org/content/pharmrev/73/3/924/F5.large.jpg
https://www.ahajournals.org/doi/10.1161/01.atv.0000034707.40046.02
https://www.ahajournals.org/cms/asset/8ff76415-3c4c-4264-a481-82fb7d04675c/jah35534-fig-0007.png
https://www.researchgate.net/publication/251478478_Pomegranate_Extract_Blocks_Ritonavir-Induced_Endothelial_Dysfunction_In_Porcine_Pulmonary_Arteries
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792423/
https://www.mdpi.com/1422-0067/20/2/294/htm
https://www.mdpi.com/ijms/ijms-20-00294/article_deploy/html/images/ijms-20-00294-g009.png
RITONAVIR causes vision loss (retina damage):
https://pubmed.ncbi.nlm.nih.gov/20966821/
https://www.aao.org/editors-choice/longterm-ritonavir-treatment-may-lead-to-retinal-p
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853367/
https://pubmed.ncbi.nlm.nih.gov/26555254/
https://pubmed.ncbi.nlm.nih.gov/27285286/
https://pubmed.ncbi.nlm.nih.gov/31046022/
https://www.sciencedirect.com/science/article/pii/S2451993619300957
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458545/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249001/
https://www.ijretina.com/index.php/ijretina/article/view/179
RITONAVIR causes hearing loss (inner ear damage):
https://pubmed.ncbi.nlm.nih.gov/11712105/
https://www.sciencedirect.com/science/article/pii/S1808869417301179
https://www.frontiersin.org/articles/10.3389/fneur.2021.725566/full
RITONAVIR causes sexual dysfunction (erectile dysfunction, loss of sex drive, sperm quality damage, testicle damage):
https://journals.lww.com/aidsonline/Fulltext/2001/05250/Sexual_dysfunction_associated_with_protease.10.aspx
https://www.aidsmap.com/news/may-2002/ritonavir-most-strongly-linked-male-sexual-dysfunction
https://www.natap.org/2002/june/060302_2.htm
https://pubmed.ncbi.nlm.nih.gov/15052987/
http://pubs.sciepub.com/ajps/2/5/4/index.html
https://pubmed.ncbi.nlm.nih.gov/26150184/
RITONAVIR causes oxidative stress and nitrosative stress (reactive oxygen species and reactive nitrogen species):
https://academic.oup.com/cardiovascres/article/63/1/168/282509
https://pubmed.ncbi.nlm.nih.gov/17668557/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787040/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841797/
https://www.sciencedirect.com/science/article/abs/pii/S0891584914000240
https://www.researchgate.net/publication/325404037_LopinavirRitonavir_Treatment_Induces_Oxidative_Stress_and_Caspaseindependent_Apoptosis_in_Human_Glioblastoma_U-87_MG_Cell_Line
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358897/
https://www.mdpi.com/1422-0067/19/8/2409/htm
RITONAVIR causes insulin resistance (new-onset diabetes):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167072/
https://pubmed.ncbi.nlm.nih.gov/24259240/
https://pubmed.ncbi.nlm.nih.gov/10852083/
https://pubmed.ncbi.nlm.nih.gov/10888979/
https://www.sciencedirect.com/science/article/abs/pii/S0166354211004463
https://source.wustl.edu/2010/11/hiv-drugs-interfere-with-blood-sugar-lead-to-insulin-resistance/
RITONAVIR causes pancreatitis (inflammation of the pancreas):
https://link.springer.com/article/10.1007/s100960050194
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111571/
https://academic.oup.com/cid/article/28/1/161/302377
https://www.thebody.com/article/an-overview-of-norvir-ritonavir
RITONAVIR causes endocrine system dysfunction (damage to adrenal glands and other glands):
https://pubmed.ncbi.nlm.nih.gov/21730243/
https://journals.sagepub.com/doi/full/10.1177/2325957414567681
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827556/
RITONAVIR causes lipolysis, lipoatrophy, lipohypertrophy, lipodystrophy (unwanted relocation of body fat), and atherosclerotic lesions:
https://academic.oup.com/cid/article/30/Supplement_2/S135/372084
https://pubmed.ncbi.nlm.nih.gov/14709251/
https://academic.oup.com/jcem/article/90/6/3251/2870553
https://www.ahajournals.org/doi/full/10.1161/01.ATV.0000194073.87647.10
https://journals.sagepub.com/doi/abs/10.3851/IMP2039
https://i-base.info/qa/775
https://pubmed.ncbi.nlm.nih.gov/22297608/
https://www.sciencedirect.com/science/article/abs/pii/S0166354212001040
https://themedicalbiochemistrypage.org/lipolysis-and-the-oxidation-of-fatty-acids/
https://en.wikipedia.org/wiki/Lipoatrophy
https://en.wikipedia.org/wiki/Lipodystrophy#Antiretroviral_drugs
https://en.wikipedia.org/wiki/HIV-associated_lipodystrophy#Presentation
https://duckduckgo.com/?q=lipoatrophy&kp=1&iar=images&iax=images&ia=images
https://duckduckgo.com/?q=lipodystrophy&kp=1&iar=images&iax=images&ia=images
https://duckduckgo.com/?q=lipohypertrophy&kp=1&iar=images&iax=images&ia=images
RITONAVIR causes hair loss (hair follicle damage):
https://pubmed.ncbi.nlm.nih.gov/17763601/
https://escholarship.org/uc/item/0n583197
https://journals.lww.com/aidsonline/fulltext/2007/06190/alopecia_associated_with_ritonavir_boosted.31.aspx
https://journals.lww.com/aidsonline/fulltext/2002/08160/generalized_hair_loss_induced_by_indinavir_plus.21.aspx
RITONAVIR causes hypermenorrhea (excessive menstrual bleeding, new-onset gastrointestinal bleeding)
https://www.proquest.com/docview/199035865
RITONAVIR causes CNS (cental nervous system) dysfunction (nerve damage):
https://penntoday.upenn.edu/news/penn-study-finds-link-between-hiv-treatment-and-neuronal-degeneration
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282963/
RITONAVIR causes intracellular dysfunction (endoplasmic reticulum damage, mitochondria damage):
https://link.springer.com/article/10.1007/s10565-018-09451-7
RITONAVIR and other HIV drugs worsen the gut microbiota (more gas, more diarrhea, and less beneficial, health-protecting, probiotic chemicals):
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0258226
RITONAVIR boosts the amount of toxic metals (arsenic, barium, beryllium, cadmium, lead, and mercury) inside of the human body by potently inhibiting CYP3A4, the most important of the hepatic, drug-metabolizing enzymes:
https://pubmed.ncbi.nlm.nih.gov/25274602/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372271/
https://ars.els-cdn.com/content/image/1-s2.0-S0278691520306992-gr2_lrg.jpg
RITONAVIR causes eryptosis (red blood cell apoptosis):
https://onlinelibrary.wiley.com/doi/10.1111/bcpt.12547
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426644/
https://en.wikipedia.org/wiki/Eryptosis
RITONAVIR causes muscle loss (muscle damage):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524660/
https://pubmed.ncbi.nlm.nih.gov/15090791/
RITONAVIR causes bone loss (bone damage):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838480/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368553/
https://www.frontiersin.org/articles/10.3389/fphys.2018.01074/full
https://pubmed.ncbi.nlm.nih.gov/25948863/
https://journals.lww.com/aidsonline/Fulltext/2002/07260/Ritonavir_associated_hyperparathyroidism,.19.aspx
https://www.natap.org/2008/CROI/croi_104.htm
https://www.thebodypro.com/article/bone-loss-similar-among-patients-taking-lopinavir-ritonavir-efavi
RITONAVIR causes hypertension (high blood pressure):
https://journals.lww.com/aidsonline/Fulltext/2006/04240/Antiretroviral_medications_associated_with.9.aspx
https://www.aidsmap.com/news/apr-2006/starting-treatment-kaletra-involves-greater-risk-increased-blood-pressure-linked-gain
https://www.aidsmap.com/news/dec-2006/severe-interaction-between-low-dose-ritonavir-and-blood-pressure-drug-observed
https://www.medpagetoday.com/opinion/skeptical-cardiologist/96692
RITONAVIR causes cognitive dysfunction (brain damage):
https://www.thebody.com/article/protease-inhibitors-linked-to-cognitive-decline-wh
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400265/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474176/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225305/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086755/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164642/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991583/
http://www.prn.org/index.php/complications/article/neurologic_complications_hiv_antiretroviral_therapy_75
RITONAVIR penetrates the blood-brain barrier and remains trapped in the brain’s capillaries:
https://pubmed.ncbi.nlm.nih.gov/14634041/
https://pubmed.ncbi.nlm.nih.gov/31209776/
RITONAVIR damages brain astrocytes (brain cell damage):
https://pubmed.ncbi.nlm.nih.gov/23341120/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732003/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581874/
RITONAVIR causes senescence (premature aging) in all cells, all organs, and all systems:
https://www.ahajournals.org/doi/10.1161/atvbaha.110.213603
https://i-base.info/htb/15951
https://pubmed.ncbi.nlm.nih.gov/23795945/
https://pubmed.ncbi.nlm.nih.gov/24535489/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270669/
https://pubmed.ncbi.nlm.nih.gov/28350300/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581874/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364271/
https://elifesciences.org/articles/62635
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629897/
https://pubmed.ncbi.nlm.nih.gov/30997718/
RITONAVIR causes hyperlipidemia and hypertriglyceridemia (blood cholesterol ratio damage):
https://academic.oup.com/cid/article/38/7/1017/320836
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392175/
RITONAVIR causes gingivitis (worsens gum health):
https://onlinelibrary.wiley.com/doi/10.1111/j.1468-1293.2010.00863.x
RITONAVIR causes cardiovascular dysfunction (heart damage):
https://www.contagionlive.com/view/ritonavir-boosted-protease-inhibitors-may-increase-risk-of-cardiovascular-disease-death
https://advances.massgeneral.org/cardiovascular/article-external.aspx?id=1033
https://www.sciencedirect.com/science/article/pii/S092544391300344X
https://ars.els-cdn.com/content/image/1-s2.0-S092544391300344X-gr2_lrg.jpg
https://www.thecardiologyadvisor.com/home/topics/arrhythmia/ritonavir-may-increase-the-risk-for-bradycardia-in-covid-19/
https://www.healio.com/news/cardiology/20200724/treatment-of-covid19-with-lopinavirritonavir-may-raise-bradycardia-risk
https://www.jacc.org/doi/full/10.1016/j.jacc.2018.04.083
https://ars.els-cdn.com/content/image/1-s2.0-S0735109718349970-gr6.jpg
https://www.natap.org/2012/images/072312/072312-5/adverse2.gif
https://www.infectiousdiseaseadvisor.com/home/topics/hiv-aids/cumulative-ritonavir-boosted-darunavir-use-may-be-associated-with-increased-cvd-risk/
https://journals.physiology.org/doi/full/10.1152/ajpregu.00268.2013
https://journals.lww.com/aidsonline/Fulltext/2017/11280/Switching_from_a_ritonavir_boosted_protease.8.aspx
https://www.umcvc.org/health-library/d04717a1
https://www.internationaljournalofcardiology.com/article/S0167-5273(20)33981-4/fulltext
RITONAVIR can reactivate hepatitis B or hepatitis C in people who have already been exposed to these 2 hepatitis viruses in the past:
https://pbs.twimg.com/media/CodczKiWIAACzYO.jpg:large
https://www.hhs.gov/hepatitis/learn-about-viral-hepatitis/data-and-trends/index.html
https://www.ncbi.nlm.nih.gov/books/NBK548301/
RITONAVIR causes hepatic steatosis (fatty liver disease):
https://www.sciencedirect.com/science/article/abs/pii/S0024320518306404
https://ars.els-cdn.com/content/image/1-s2.0-S0024320518306404-ga1_lrg.jpg
https://www.mdpi.com/cells/cells-10-01687/article_deploy/html/images/cells-10-01687-g001.png
https://www.wjgnet.com/1007-9327/full/v26/i32/WJG-26-4753-g001.htm
https://www.researchgate.net/figure/FXR-and-PPAR-a-ligands-attenuate-liver-steatosis-induced-by-the-HIV-protease-inhibitor_fig10_47430514
https://www.researchgate.net/figure/Exposure-to-ritonavir-causes-SREBP1c-activation-in-the-liver-and-monocytes-In_fig8_47430514
https://pubmed.ncbi.nlm.nih.gov/31219362/
https://pubmed.ncbi.nlm.nih.gov/32490327/
https://twitter.com/hepcommjournal/status/1295692323033174016/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597219/
RITONAVIR causes renal calculi or nephrolithiasis (kidney stones that are composed of pure ritonavir):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605930/
https://www.sciencedirect.com/science/article/pii/S2214442021002035
https://www.consultant360.com/articles/protease-inhibitor-induced-nephrolithiasis
https://www.empr.com/home/news/stone-formation-in-an-hiv-patient-two-years-after-stopping-ritonavir/
https://speciality.medicaldialogues.in/hiv-patient-develops-ritonavir-induced-kidney-stone-2-years-after-stopping-it-bmj-case-report
RITONAVIR causes renal dysfunction (kidney damage):
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)65125-2/fulltext
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727453/
https://journals.lww.com/aidsonline/Fulltext/2020/06010/HIV_protease_inhibitor_ritonavir_induces_renal.3.aspx
https://www.kireports.org/article/S2468-0249(20)31434-0/fulltext
https://journals.lww.com/aidsonline/Fulltext/2014/03130/Antiretrovirals_and_the_kidney_in_current_clinical.1.aspx
https://www.natap.org/2016/images/010616/010616-1/HIV1.gif
https://academic.oup.com/jid/article/207/9/1349/929238
https://journals.lww.com/aidsonline/fulltext/2015/02200/acute_interstitial_nephritis_caused_by.12.aspx
NIRMATRELVIR causes even more renal dysfunction (kidney damage) than ritonavir:
https://www.ismp.org/alerts/medication-safety-issues-newly-authorized-paxlovid
https://www.healthnavigator.org.nz/paxlovid/
PAXLOVID or RITONAVIR (swallowed alone) can sometimes cause hives (skin rash):
https://academic.oup.com/jac/article/62/5/879/722729
https://pubmed.ncbi.nlm.nih.gov/24507978/
https://pubmed.ncbi.nlm.nih.gov/15757820/
https://elsevier.health/en-US/preview/nirmatrelvir-ritonavir-oral-tablets-paxlovid
https://en.wikipedia.org/wiki/Hives#/media/File:EMminor2010.JPG
PAXLOVID or RITONAVIR (swallowed alone) always causes a bitter, metallic taste:
https://www.wikidoc.org/index.php/Ritonavir_description
https://pubmed.ncbi.nlm.nih.gov/10501290/
https://www.yahoo.com/entertainment/heres-why-many-people-talking-165700302.html
PAXLOVID can sometimes cause dysgeusia (loss or alteration of taste):
https://medicalxpress.com/news/2022-05-covid-affected-paxlovid-mouth-disgusting.html
PAXLOVID is a nightmare for organ transplant recipients, for whom Paxlovid is frequently prescribed because they qualified for it by being “high-risk” for bad outcomes from COVID-19:
https://www.medpagetoday.com/transplantation/transplantation/98708
We’ll see if Pfizer, Shionogi, Enanta, Todos, Zhongsheng, and Simcere can live up to their exaggerated claims after the bad side effects and inadequate efficacies of their protease inhibitors are first discovered in unauthorized foreign research studies:
https://www.frontiersin.org/files/Articles/616595/fimmu-11-616595-HTML/image_m/fimmu-11-616595-g001.jpg
Dozens of 3CL protease inhibitors have been discovered, ranging from very safe (vitamin B12) to poorly tolerated (cancer chemotherapy drugs):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062204/
https://www.researchgate.net/publication/339417253/figure/tbl2/AS:861196089577472@1582336556237/Possible-side-effects-and-routes-of-administration-of-the-drugs-identified-from-virtual.png
https://pubs.acs.org/doi/10.1021/acsptsci.0c00108
HIV-1 protease inhibitors for treating human immunodeficiency virus (HIV) are highly vulnerable to viral drug resistance:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912444/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772045/
https://www.medicalnewstoday.com/articles/323872#side-effects
https://hivdb.stanford.edu/dr-summary/resistance-notes/PI/
NS3/4A protease inhibitors for treating hepatitis C virus (HCV) are highly vulnerable to viral drug resistance:
https://www.sciencedirect.com/science/article/pii/S0168827811000791
3CL proteae inhibitors, including nirmatrelvir, are highly vulnerable to viral drug resistance:
https://www.biorxiv.org/content/10.1101/2022.06.07.495116v1.full
https://www.biorxiv.org/content/10.1101/2022.06.06.494921v1.full
https://www.biorxiv.org/content/10.1101/2022.06.28.497978v1.full
https://www.news-medical.net/news/20220630/SARS-CoV-2-can-evade-Paxlovid-by-multiple-mechanisms.aspx
https://www.coronaheadsup.com/health/treatment/paxlovid/science-mag-sars-cov-2-already-finding-ways-to-evade-paxlovid/
https://www.biorxiv.org/content/10.1101/2022.07.02.495455v1.full
https://www.news-medical.net/news/20220706/Paxlovid-resistance-associated-with-SARS-CoV-2-3CLpro-mutations.aspx
https://www.biorxiv.org/content/10.1101/2022.07.12.499687v1.full
Researcher Rong Xu of Cleveland, Ohio says that the SARS-CoV-2 virus has already evolved a drug resistance to Paxlovid. In his 8-4-2022 study, Omicron BA.5 was already 32% more likely to cause a Paxlovid viral rebound than Omicron BA.2.12.1:
https://www.medrxiv.org/content/10.1101/2022.08.04.22278450v1.full
However, RNA-dependent RNA polymerase (RdRp) inhibitors (favipiravir, ribavirin) are less likely to encounter viral drug resistance. Ribavirin, which was invented in 1971 and first approved in 1986, continues to be used today to treat hepatitis C virus (HCV) patients:
https://www.antimicrobe.org/drugpopup/ribavirin.htm
https://pubmed.ncbi.nlm.nih.gov/32097670/
https://www.sciencedirect.com/science/article/abs/pii/S0166354222001565
Although most governments have been eager to purchase and try both Paxlovid and molnupiravir, the demand among the people for these 2 poorly tested antivirals has been unexpectedly low. This has forced the US FDA to extend the shelf life of Paxlovid to prevent huge quantities of this expensive (inflationary) drug from being discarded into the trash can by pharmacists:
https://publications.aap.org/aapnews/news/19938/FDA-extends-shelf-life-of-COVID-antiviral-Paxlovid
https://www.infectiousdiseaseadvisor.com/home/topics/covid19/fda-extends-shelf-life-of-certain-lots-of-covid-19-antiviral-paxlovid/
https://www.theglobeandmail.com/canada/article-covid-19-antiviral-drug-paxlovid-being-dispensed-at-low-rates-across/
https://www.npr.org/sections/health-shots/2022/03/18/1087380770/lifesaving-covid-drugs-are-sitting-unused-on-pharmacy-shelves-hhs-data-shows
https://www.sfchronicle.com/health/article/S-F-health-officials-return-thousands-of-17062896.php
https://www.cidrap.umn.edu/news-perspective/2022/02/eagerly-awaited-covid-lifesavers-molnupiravir-paxlovid-now-wait-patients
https://www.citizensvoice.com/news/coronavirus/anti-covid-19-pills-more-available-but-demand-down/article_13d8228e-e2e8-5495-a369-6611a514617c.html
https://timesofindia.indiatimes.com/city/nagpur/experts-divided-over-use-of-molnupiravir-low-demand-for-drug/articleshow/88818929.cms
https://www.wsj.com/articles/highly-touted-monoclonal-antibody-therapies-sit-unused-in-hospitals-11609087364
https://www.bridgemi.com/michigan-health-watch/why-stockpile-promising-covid-19-treatment-sits-unused-lansing
https://www.freep.com/story/news/health/2022/04/11/covid-19-antiviral-treatments-monoclonal-antibodies-unused-michigan/9512596002/
https://abc7chicago.com/paxlovid-side-effects-availability-covid-pill-interactions/11738642/
https://www.cbc.ca/news/canada/calgary/paxlovid-covid-transmission-grows-alberta-1.6417098
https://sports.yahoo.com/thousands-covid-19-treatments-sit-100015838.html
https://www.nzdoctor.co.nz/article/news/covid-antiviral-uptake-lower-expected
https://www.dailymail.co.uk/health/article-10719697/Nearly-600-000-course-Pfizers-Paxlovid-sitting-UNUSED-America.html
https://www.reuters.com/business/healthcare-pharmaceuticals/demand-pfizers-covid-pills-lags-around-world-2022-04-19/
https://www.kpbs.org/news/midday-edition/2022/04/18/supplies-of-covid-19-antiviral-pill-paxlovid-are-abundant-as-demand-lessens
https://www.fiercepharma.com/pharma/pfizers-covid-19-antiviral-paxlovid-hits-worldwide-demand-slump
https://seekingalpha.com/news/3824295-demand-for-pfizer-covid-19-antiviral-paxlovid-not-as-high-as-expected-reuters
https://newyork.forumdaily.com/en/pakslovid-ot-pfizer-nazyvali-proryvom-v-lechenii-covid-19-kuda-ischez-etot-preparat-obeshhavshij-stat-revolyucionnym/
https://www.khmertimeskh.com/501060021/sharp-drop-in-molnupiravir-use-as-infections-get-milder/
https://www.union-bulletin.com/seattle_times/why-aren-t-doctors-prescribing-anti-covid-medicines/article_57d827a9-6b18-5b43-b483-f9afaf7208d6.html
https://adnamerica.com/en/united-states/pfizers-covid-19-pill-supply-outstrips-demand
https://www.ruetir.com/2022/04/21/antiviral-paxlovid-from-the-family-doctor-bassetti-yet-another-thing-done-wrong/
https://www.medrxiv.org/content/10.1101/2022.04.21.22274155v1
https://fox59.com/news/coronavirus/indiana-providers-prescribing-paxlovid-to-handful-of-covid-19-patients/
https://www.ctinsider.com/news/article/CT-has-12-000-free-Paxlovid-doses-to-treat-COVID-17157429.php
https://www.taipeitimes.com/News/editorials/archives/2022/05/15/2003778210
https://www.fool.com/investing/2022/05/17/pfizers-setbacks-with-paxlovid-are-mounting-should/
https://pbswisconsin.org/news-item/wisconsins-covid-condition-antiviral-use-low-as-another-omicron-wave-builds/
https://www.irishtimes.com/news/health/only-65-doses-of-covid-antiviral-pill-administered-to-irish-patients-1.4882251
https://www.irishtimes.com/health/2022/06/13/fewer-than-170-doses-of-game-changer-covid-19-drug-given-to-irish-patients/
https://www.surinenglish.com/spain/spain-pfizer-covid-treatments-20220606173736-nt.html
https://www.fox5vegas.com/2022/06/14/not-enough-people-sick-with-covid-19-getting-eligible-medications-snhd-says/
https://carolinapublicpress.org/54665/covid-19-medications-widely-available-in-nc-but-how-are-they-being-used/
https://www.news-medical.net/news/20220616/At-a-Bay-Area-e28098test-to-treate28099-site-few-takers-for-free-antivirals.aspx
https://khn.org/news/article/covid-antiviral-community-test-to-treat-berkeley-california/
https://prress.com/health/covid-antivirals-paxlovid-does-not-even-take-off-in-the-pharmacy-in-a-month-only-2-thousand-treatments/
https://www.theguardian.com/australia-news/2022/jul/22/government-urges-take-up-of-covid-antivirals-as-almost-500000-in-australian-stockpile-near-expiry-date
https://www.forbes.com/sites/roberthart/2022/07/25/weak-demand-for-covid-antivirals-dampens-roaring-sales/
https://www.beckershospitalreview.com/supply-chain/as-pfizer-s-antiviral-use-decreases-70m-paxlovid-packs-could-be-left-over.html
Merck recently reminded us that ritonavir-boosted protease inhibitors, including Pfizer’s Paxlovid, have the longest list of bad drug interactions of any drugs in history. Although both nirmatrelvir and ritonavir are pro-oxidants that will damage every cell in the human body if used longer than 5 days, ritonavir causes 621 out of the 627 bad drug interactions caused by Paxlovid, while ritonavir causes 221 out of the 227 “major” bad drug interactions caused by Paxlovid:
https://www.ft.com/content/7ded2361-e797-465e-ac25-a42c1d899881
https://www-echo24-de.translate.goog/welt/paxlovid-corona-medikament-probleme-wechselwirkung-wirkstoffe-studien-ritonavir-91378715.html?_x_tr_sl=de&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
https://twitter.com/absteward/status/1476758865790259205
https://www.drugs.com/drug-interactions/paxlovid-with-remdesivir-4326-19915-4146-0.html
https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/management-of-drug-interactions-with-nirmatrelvirritonavir-paxlovid/
https://www.sciencedirect.com/science/article/pii/S0040595722000658
https://www.drugs.com/drug-interactions/remdesivir.html
https://www.drugs.com/drug-interactions/ritonavir.html
https://www.drugs.com/drug-interactions/nirmatrelvir-ritonavir,paxlovid.html
In their rush to dispense Paxlovid within the 5-day time limit, proper coaching and screening for Paxlovid’s 627 bad drug interactions isn’t being done:
https://news.bloomberglaw.com/health-law-and-business/pfizer-covid-pill-access-stymied-by-vague-prescribing-guidance
https://www.pharmacypracticenews.com/Covid-19/Article/07-22/ISMP-Issues-Warning-About-Paxlovid-Errors/67406
https://www.nwahomepage.com/news/some-doctors-hesitant-to-prescribe-anti-viral-pill/
https://academic.oup.com/cid/article/37/5/e72/312798
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085857/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277654/
Ritonavir causes all of its drug interactions by interfering with hepatic cytochrome P450, notably the 3A4 subtype, CYP3A4, which is the key enzyme for metabolizing most drugs.
P-glycoprotein (P-gp) is the name of the transporter which boosts the concentration of many drugs.
Many people say that their COVID-19 viral load and symptoms got better, then worse, after swallowing Paxlovid:
https://www.coronaheadsup.com/health/treatment/paxlovid/paxlovid-covid-19-infections-rebounding-a-few-days-after-treatment/
https://www.bostonglobe.com/2022/04/21/metro/puzzling-phenomenon-patients-report-rebound-covid-19-symptoms-after-taking-antiviral-paxlovid/
https://www.dailymail.co.uk/health/article-10744285/Recipients-Paxlovid-report-symptoms-returning-testing-positive-virus-again.html
https://twitter.com/DrEricDing/status/1517338915031683072/
https://www.realclearscience.com/2022/04/23/the_paxlovid_rebound_problem_is_real_828595.html
https://www.acsh.org/news/2022/04/26/covid-rebound-following-paxlovid-therapy-should-we-worry-16272
https://www.slashgear.com/845448/covid-19-is-recurring-in-patients-who-took-pfizers-antiviral-doctors-dont-know-why/
https://news.yahoo.com/covid-symptoms-may-return-taking-143245890.html
https://heromag.net/another-rare-virus-puzzle-they-got-sick-got-treated-got-covid-again
https://www.sciencetimes.com/articles/37379/20220428/covid-19-reinfects-people-who-took-pfizer-antivirus-treatment.htm
https://www.bloomberg.com/news/articles/2022-04-29/u-s-seeks-urgent-data-on-covid-relapses-after-pfizer-drug
https://twitter.com/EricTopol/status/1519664698865508353/
https://blogs.jwatch.org/hiv-id-observations/index.php/more-on-relapses-after-paxlovid-treatment-for-covid-19/2022/05/04/
https://twitter.com/DrEricDing/status/1521723944851714048/
https://twitter.com/DrEricDing/status/1522024332427509761/
https://pbs.twimg.com/media/FR9REDUX0AMclxY.jpg:large
https://rumble.com/v13se1n-pfizer-ceo-commits-federal-crimes-peddling-paxlovid-off-label.html
https://www.statnews.com/2022/05/24/paxlovid-rebound-has-covid-researchers-looking-for-theories/
https://theskepticalcardiologist.com/2022/06/13/rebound-symptoms-after-paxlovid-for-covid-19-many-cases-and-many-unanswered-questions/
https://www.yahoo.com/entertainment/fauci-says-experienced-paxlovid-rebound-200935592.html
Reports are emerging of the restarting of full-fledged COVID-19 among people who swallowed Paxlovid:
https://news.yahoo.com/covid-19-mystery-getting-coronavirus-143757835.html
Here’s the fake Mayo Clinic study that Pfizer controlled with their bribe money. It made news headlines claiming that Pfizer’s Paxlovid has a viral load rebound rate of less than 1%. Don’t trust any of Pfizer’s claims for anything:
https://newsnetwork.mayoclinic.org/discussion/study-finds-few-covid-19-patients-get-rebound-symptoms-after-paxlovid-treatment/
https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciac481/6607746
Many doctors now suspect that Paxlovid’s viral load rebound happens in 30% to 40% of all people who swallow it, possibly because Paxlovid is a pro-oxidant that damages the immune system more than RdRp inhibitors, which are not pro-oxidants:
https://paperwriter.ca/the-covid-reinfection-rate-with-the-treatment-biden-is-taking-is-more-than-40-not-2-as-marketed
https://www.thegatewaypundit.com/2022/07/oops-ineffective-pfizer-covid-drug-paxlovid-administered-joe-biden-last-week-40-re-infection-rate-bummer-joe-biden/
https://flipboard.com/topic/pfizer/covid-reinfection-rate-with-treatment-biden-is-taking-is-more-than-40—and-not/a-9y2Nc7ktSEaBV7Jg7aIRTA%3Aa%3A2679765603-056c61c3a8%2Fco.uk
https://www.dailymail.co.uk/news/article-11065467/COVID-reinfection-rate-treatment-Biden-taking-40-not-2-marketed.html
Researcher Eric Dai of Boston, Massachusetts says that Paxlovid had a viral load rebound rate of 27.27% in his 8-4-2022 study:
https://www.medrxiv.org/content/10.1101/2022.08.04.22278378v1.full
In his 5-31-2022 study, Dr. Michael Charness of the VA Medical Center in Boston warns that Paxlovid swallowers can still be superspreaders, even if if they were among the 10% to 20% of Paxlovid swallowers who tested false negative on Day 2:
https://www.forbes.com/sites/madelinehalpert/2022/05/31/rebound-covid-infections-some-contagious-even-after-taking-antiviral-paxlovid-paper-suggests/
https://journalstar.com/townnews/medicine/coronavirus-can-be-contagious-during-a-paxlovid-rebound-researchers-warn-even-if-people-dont-have/article_cedc74cb-c554-5596-b0c4-95011d34645b.html
https://www.nature.com/articles/d41586-022-02026-x
https://www.business-standard.com/article/current-affairs/covid-paxlovid-rebound-can-be-contagious-even-with-no-symptoms-says-study-122073100720_1.html
Although more than 20 different health professionals have viciously attacked the fraudulent drug, remdesivir, on the internet, Dr. David Gortler is the clear leader among those who continuously criticize Paxlovid, the US FDA, and the corrupt politicians who take the bribe money from Pfizer:
https://www.conservativereview.com/if-paxlovid-causes-more-covid-why-has-the-white-house-spent-billions-on-it-2657799843.html
Dr. Buzz Hollander, Dr. Robert Malone, and Dr. Richard Urso have also criticized Paxlovid on the internet:
https://doctorbuzz.substack.com/p/president-bidens-paxlovid-and-the
https://rwmalonemd.substack.com/p/paxlovid-escape-mutations
https://thepatriotlight.com/paxlovid-shown-to-be-toxic-even-though-recommended-for-covid-treatment/
Pfizer takes advantage of a corrupt U.S. law that allows pharma companies to block all scientific studies that they don’t control with their billions of dollars in bribe money. Pfizer especially fears scientific studies that force Paxlovid to be compared in efficacy against molnupiravir, favipiravir, or Shionogi’s Xocova (ensitrelvir):
https://c19early.com/ledford.html
https://pubmed.ncbi.nlm.nih.gov/35379975/
https://www.bnnbloomberg.ca/pfizer-s-tight-paxlovid-rein-stymies-drug-combination-research-1.1767525
Here’s the truth about Paxlovid in Hong Kong, which first received Paxlovid on 3-14-2022, which is AFTER their Omicron wave had nearly ended:
https://www.info.gov.hk/gia/general/202203/15/P2022031500280.htm
By 4-23-2022, Hong Kong’s Omicron wave had ended:
https://www.google.com/search?q=hong+kong+covid-19+cases
Hong Kong reported on 4-23-2022 that almost nobody had been prescribed Paxlovid between 3-14-2022 and 4-23-2022, when Paxlovid was, and still is, in abundant oversupply:
https://www.scmp.com/news/hong-kong/health-environment/article/3175289/hong-kong-health-authorities-report-few-patients
In the Pfizer-funded, Hong Kong clinical trial by Cheuk Fung Yip, molnupiravir had 17% more hospitalizations than the control group, while Paxlovid had only 21% less hospitalizations than the control group, not 89% less hospitalizations than the control group as Pfizer had been claiming:
https://twitter.com/emlitofnote/status/1528860784201461761/
https://pbs.twimg.com/media/FTeZ96JagAAF53t.jpg:large
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4112160
“Conclusion: Both antivirals did not reduce the risk of COVID-19-associated ventilator use, ICU occupancy, or death:”
https://timetotimes.com/the-effectiveness-of-molnupiravir-and-nirmatrelvir-ritonavir-in-reducing-hospitalization-and-deaths-in-non-hospitalized-covid-19-patients/
https://c19mp.com/yip.html
https://c19early.com/yip.html
https://c19early.com/yippl.html
In the Pfizer-funded, Israeli clinical trial by Ronen Arbel, in the 40-to-64 age bracket, Paxlovid had only 22% less hospitalizations than the control group, not 89% less hospitalizations than the control group as Pfizer had been claiming. In the 40-to-64 age bracket, Paxlovid INCREASED mortality by 64%:
https://www.israelnationalnews.com/news/354306
Of the 42,819 Israelis over age 65 who were eligible, only 2,504 of them, or 5.85% of them, agreed to swallow the Paxlovid pills, while 94.15% of these 42,819 Israelis refused.
Of the 66,394 Israelis aged 40-to-64 who were eligible, only 1,435 of them, or 2.16% of them, agreed to swallow the Paxlovid pills, while 97.84% of these 66,394 Israelis refused.
“and even those in the older [65-plus age] group who were vaccinated or recovered saw [only] a relatively small benefit from Paxlovid:”
https://www.washingtonpost.com/business/doctors-are-still-flying-blind-with-paxlovid/2022/06/03/5157e924-e331-11ec-ae64-6b23e5155b62_story.html
https://c19early.com/arbel.html
On 5-24-2022, Shanghai Junshi Biosciences reported that their nucleoside analog (RdRp inhibitor), VV116 (JT001), defeated the 3C-like protease (3CLpro) inhibitor, Paxlovid, in a Phase 3 clinical trial. The VV116 molecule is more similar to the molecule of Gilead Sciences’ GS-441524 than to the molecules of the nucleoside analogs, ribavirin, favipiravir, or molnupiravir:
https://finance.yahoo.com/news/vv116-versus-paxlovid-phase-iii-032200973.html
In India, on 1-12-2022, the Indian Council of Medical Research (ICMR) dropped molnupiravir from India’s national treatment protocol for COVID-19:
https://timesofindia.indiatimes.com/india/icmr-reiterates-concerns-on-molnupiravir-use-in-covid-treatment/articleshow/88860355.cms
https://img.etimg.com/photo/msid-92190145,imgsize-45408/Lukewarm.jpg
In India, on 5-7-2022, the Indian Council of Medical Research (ICMR) dropped Paxlovid from India’s national treatment protocol for COVID-19:
https://medicaldialogues.in/news/industry/pharma/paxlovid-not-be-included-in-national-treatment-guidelines-for-covid-19-says-icmr-92587
oh please.